Generex Biotechnology Corporation Signs Agreement With Cardinal Health (North Carolina) For Generex Oral-lyn(TM) Manufacturing For Clinical Trials

TORONTO--(MARKET WIRE)--Jun 22, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News), a leader in the area of buccal drug delivery, announced today that it has entered into contractual arrangements with Cardinal Health, Inc. (NYSE:CAH - News), the leading provider of products and services supporting the health-care industry, to manufacture clinical trial batches of Generex Oral-lyn(TM), a proprietary oral insulin spray product.